These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8514648)

  • 1. Synergic activity of imipenem/cilastatin combined with cefotiam against methicillin-resistant Staphylococcus aureus.
    Oka S; Goto M; Kaji Y; Kimura S; Matsuda K; Asahi Y; Sanada M; Nakagawa S; Inoue M; Shimada K
    J Antimicrob Chemother; 1993 Apr; 31(4):533-41. PubMed ID: 8514648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined effects of vancomycin and imipenem against methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo.
    Totsuka K; Shiseki M; Kikuchi K; Matsui Y
    J Antimicrob Chemother; 1999 Oct; 44(4):455-60. PubMed ID: 10588305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of combinations of cefotiam and other antibiotics on methicillin-resistant Staphylococcus aureus in vitro.
    Sugiura A; Jono K; Kono T; Higashide E
    J Antimicrob Chemother; 1991 Nov; 28(5):707-17. PubMed ID: 1778874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic enhancement of in vitro antimicrobial activity of imipenem and cefazolin, cephalothin, cefotiam, cefamandole or cefoperazone in combination against methicillin-sensitive and -resistant Staphylococcus aureus.
    Uete T; Matsuo K
    Jpn J Antibiot; 1995 Mar; 48(3):402-8. PubMed ID: 7752453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro activity of imipenem combined with beta-lactam antibiotics for methicillin-resistant Staphylococcus aureus.
    Matsuda K; Asahi Y; Sanada M; Nakagawa S; Tanaka N; Inoue M
    J Antimicrob Chemother; 1991 Jun; 27(6):809-15. PubMed ID: 1938687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical effect of the combined therapy of arbekacin and imipenem/cilastatin against methicillin-resistant Staphylococcus aureus].
    Hashimoto A; Ohtsubo T; Tomono K; Kaku M; Koga H; Kohno S; Hara K; Sugiyama H; Taira K; Inoue Y
    Jpn J Antibiot; 1994 Jun; 47(6):804-12. PubMed ID: 8072190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Basic studies on combination effects of arbekacin and beta-lactam antibiotics on methicillin-resistant Staphylococcus aureus].
    Watanabe T; Sobu K; Takase Y; Kawabata T; Kanno M; Yoshida T
    Jpn J Antibiot; 1994 Jun; 47(6):701-9. PubMed ID: 8072178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bacteriological evaluations of combination effects with cefotiam and other antimicrobial agents against methicillin-resistant Staphylococcus aureus. I. Synergistic actions of cefotiam with imipenem and vancomycin].
    Deguchi K; Yokota N; Koguchi M; Suzuki Y; Suzuki K; Fukayama S; Ishihara R
    Jpn J Antibiot; 1993 Feb; 46(2):115-22. PubMed ID: 8331771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autolysis of methicillin-resistant Staphylococcus aureus is involved in synergism between imipenem and cefotiam.
    Matsuda K; Nakamura K; Adachi Y; Inoue M; Kawakami M
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2631-4. PubMed ID: 8592992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro effects of combinations of antibiotics against highly-fosfomycin-resistant, methicillin-resistant Staphylococcus aureus. With special reference to efficacies of combinations of imipenem/cilastatin and cephems].
    Kouda M
    Jpn J Antibiot; 1993 Feb; 46(2):142-53. PubMed ID: 8331774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Revaluation of current antimicrobials. Series 24: imipenem/cilastatin].
    Kohno S; Wada K
    Jpn J Antibiot; 1994 Dec; 47(12):1629-36. PubMed ID: 7877247
    [No Abstract]   [Full Text] [Related]  

  • 12. [Efficacy of arbekacin, a new aminoglycoside antibiotic, in surgical patients with MRSA infections].
    Ishikawa S; Yura J; Shinagawa N; Mizuno A; Mashita K; Hori K
    Jpn J Antibiot; 1994 Jun; 47(6):820-5. PubMed ID: 8072192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics in nonhuman primates of a prototype carbapenem active against methicillin-resistant Staphylococcus aureus.
    Sundelof JG; Thompson R; White KM; Sasor MW; Cama L; Kropp H
    Antimicrob Agents Chemother; 1996 Mar; 40(3):795-8. PubMed ID: 8851616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus.
    Jacqueline C; Navas D; Batard E; Miegeville AF; Le Mabecque V; Kergueris MF; Bugnon D; Potel G; Caillon J
    Antimicrob Agents Chemother; 2005 Jan; 49(1):45-51. PubMed ID: 15616274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacies of imipenem-cilastatin and vancomycin in experimental aortic valve endocarditis due to methicillin resistant Staphylococcus aureus.
    Chandrasekar PH; Levine DP; Price S; Rybak MJ
    J Antimicrob Chemother; 1988 Apr; 21(4):461-9. PubMed ID: 3378959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic efficacy of BO-3482, a novel dithiocarbamate carbapenem, in mice infected with methicillin-resistant Staphylococcus aureus.
    Nagano R; Shibata K; Naito T; Fuse A; Asano K; Hashizume T; Nakagawa S
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2278-81. PubMed ID: 9333062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of arbekacin, alone and in combination, against methicillin-resistant Staphylococcus aureus.
    Kono K; Takeda S; Tatara I; Arakawa K
    Jpn J Antibiot; 1994 Jun; 47(6):710-9. PubMed ID: 8072179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Enhancement of in vitro antimicrobial activity of cefmetazole and cefotiam in combination against methicillin-susceptible and -resistant Staphylococcus aureus studied using checkerboard MIC method and disc diffusion method with discs containing both drugs].
    Matsuo K; Uete T
    Jpn J Antibiot; 1993 Mar; 46(3):222-33. PubMed ID: 8510319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
    Ong CT; Kuti JL; Nicolau DP;
    Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bacteriological evaluations of combination effects with cefotiam and other antimicrobial agents against methicillin-resistant Staphylococcus aureus. II. Synergistic actions of cefotiam with arbekacin and minocycline].
    Deguchi K; Yokota N; Koguchi M; Suzuki Y; Suzuki K; Fukayama S; Ishihara R
    Jpn J Antibiot; 1993 Feb; 46(2):123-9. PubMed ID: 8331772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.